Form 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended June 30, 1997
Commission File No. 000-19495
Embrex, Inc.
(Exact name of issuer as specified in its charter)
North Carolina 56-1469825
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
1035 Swabia Court, Durham, NC 27703
(Address of principal executive offices) (Zip Code)
Registrant's telephone no. including area code: (919) 941-5185
Check whether the registrant (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.
Yes X No_____
The number of shares of Common Stock, $0.01 par value, outstanding as of July
31, 1997, was 8,234,660.
<PAGE>
EMBREX, INC.
INDEX
Part I Page
Financial Information:
Item 1:
Balance Sheets...........................................3 of 13
Statements of Operations.................................4 of 13
Statements of Cash Flows.................................5 of 13
Notes to Consolidated Financial Statements...............6 of 13
Item 2:
Management's Discussion and Analysis of
Financial Condition and Results of Operations............7 of 13
Item 3:
Quantitative and Qualitative Disclosures
About Market Risk.......................................10 of 13
Part II
Other Information:
Item 1: Legal Proceedings.......................................10 of 13
Item 2: Changes in Securities...................................10 of 13
Item 3: Defaults Upon Senior Securities.........................10 of 13
Item 4: Submission of Matters to a Vote of Security Holders 11 of 13
Item 5: Other Information.......................................11 of 13
Item 6: Exhibits and Reports on Form 8-k........................11 of 13
Signatures......................................................12 of 13
Exhibit Index...................................................13 of 13
<PAGE>
PART I - FINANCIAL INFORMATION
Item 1 - Financial Statements
Embrex, Inc.
CONSOLIDATED BALANCE SHEETS
(DOLLARS IN THOUSANDS)
<TABLE>
<CAPTION>
JUNE 30 DECEMBER 31
1997 1996
-------- --------
(UNAUDITED)
<S> <C> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents .............................................. $ 9,604 $ 9,036
Short-term investments ................................................. 0 876
Inventories:
Materials and supplies ............................................. 1,095 1,061
Product ............................................................ 406 573
Accounts receivable - trade ............................................ 2,549 2,313
Other current assets ................................................... 389 124
-------- --------
TOTAL CURRENT ASSETS ............................................... 14,043 13,983
INOVOJECT(R)SYSTEMS UNDER CONSTRUCTION ..................................... 670 530
INOVOJECT(R)SYSTEMS ........................................................ 19,810 18,193
Less accumulated depreciation .......................................... (10,204) (8,499)
-------- --------
9,606 9,694
EQUIPMENT, FURNITURE AND FIXTURES .......................................... 2,781 2,607
Less accumulated depreciation and amortization ......................... (1,840) (1,695)
-------- --------
941 912
OTHER ASSETS:
Goodwill, patents, and exclusive licenses of patentable technology
(net of accumulated amortization of $64 in 1997 and $58 in 1996) ... 307 125
Other non-current assets ............................................... 79 310
-------- --------
TOTAL ASSETS ............................................................... $ 25,646 $ 25,554
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities
Accounts payable ....................................................... $ 1,582 $ 1,355
Accrued expenses ....................................................... 1,463 1,087
Current portion of capital lease obligations ........................... 3,024 3,080
Current portion of long-term debt ...................................... 426 909
-------- --------
TOTAL CURRENT LIABILITIES .......................................... 6,495 6,431
CAPITAL LEASE OBLIGATIONS, less current portion ............................ 4,331 5,806
LONG-TERM DEBT, less current portion ....................................... 12 8
SHAREHOLDER'S EQUITY Common Stock, $.01 par value:
Authorized - 30,000,000 shares
Issued and outstanding -
8,220,046 and 8,043,490 shares at June 30, 1997 and
December 31, 1996, respectively ................................ 82 80
Additional paid-in capital ............................................. 54,643 53,742
Currency translation adjustments ....................................... 97 180
Accumulated deficit .................................................... (40,014) (40,693)
-------- --------
TOTAL SHAREHOLDERS' EQUITY ......................................... 14,808 13,309
-------- --------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY ................................. $ 25,646 $ 25,554
======== ========
</TABLE>
3
<PAGE>
Embrex, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30 JUNE 30
--------------------- ------------------
1997 1996 1997 1996
---- ---- ---- ----
<S> <C> <C> <C> <C>
REVENUES
INOVOJECT(R)SYSTEM revenue................................ $ 5,619 $ 4,621 $11,287 $ 8,941
Product sales.......................................... 293 413 499 635
Other revenue.......................................... 10 34 61 87
----------- --------- ------- ---------
TOTAL REVENUES....................................... 5,922 5,068 11,847 9,663
COST OF PRODUCT SALES AND INOVOJECT(R)SYSTEM REVENUES...... 2,911 2,685 5,733 5,151
------- ------ ------- -------
GROSS PROFIT........................................ 3,011 2,383 6,114 4,512
OPERATING EXPENSES
General and administrative.............................. 1,250 902 2,614 1,680
Sales and marketing..................................... 172 69 371 137
Research and development............................... 981 877 1,996 1,659
-------- ------- ------- -------
TOTAL OPERATING EXPENSES............................ 2,403 1,848 4,981 3,476
OPERATING INCOME........................................... 608 535 1,133 1,036
OTHER INCOME (EXPENSE)
Interest income........................................ 122 84 245 156
Interest expense....................................... (282) (399) (605) (843)
-------- -------- --------- --------
TOTAL OTHER EXPENSE................................ (160) (315) (360) (687)
-------- -------- ---------- --------
INCOME BEFORE TAXES........................................ 448 220 773 349
INCOME TAXES................................................ (31) (27) (94) (98)
--------- ----------- -------- --------
NET INCOME .......................................... $ 417 $ 193 $ 679 $ 251
======== ======== ======== ========
Net income per share of Common Stock........................ $ .05 $ .03 $ .08 $ .03
========= ========= ========= =========
WEIGHTED AVERAGE SHARES OF
COMMON STOCK OUTSTANDING (in thousands).................. 8,373 7,317 8,306 7,178
</TABLE>
4
<PAGE>
Embrex, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(DOLLARS IN THOUSANDS)
<TABLE>
<CAPTION>
SIX MONTHS ENDED JUNE 30
1997 1996
---- ----
<S> <C> <C>
OPERATING ACTIVITIES
Net income ................................................................ $ 679 $ 251
Adjustments to reconcile net income to net cash (used in) provided by
operating activities:
Depreciation and amortization........................................... 1,871 1,828
Changes in operating assets and liabilities:
Accounts receivable, inventories and other current assets.......... (448) (794)
Accounts payable and accrued expenses.............................. 669 (325)
-------- ---------
NET CASH PROVIDED BY OPERATING ACTIVITIES ...................................... 2,771 960
------ --------
INVESTING ACTIVITIES
Purchases of short-term investments......................................... 876 464
Purchases of INOVOJECT(R)systems, equipment, furniture and fixtures (1,713) (2,313)
Decrease in other noncurrent assets........................................ 36 97
----------- ---------
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES............................ (801) (1,752)
---------- --------
FINANCING ACTIVITIES
Issuance of common stock................................................... 185 259
Additions to long-term debt............................................... 4 476
Payments on long-term debt ................................................ (60) 0
Proceeds from capital lease obligations................................... 35 1,853
Payments on capital lease obligations....................................... (1,566) (1,313)
------- --------
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES............................ (1,402) 1,275
------- --------
INCREASE IN CASH AND CASH EQUIVALENTS .......................................... 568 483
Cash and cash equivalents at beginning of period........................... 9,036 5,354
--------- -------
CASH AND CASH EQUIVALENTS AT END OF PERIOD....................................... $ 9,604 $ 5,837
======== =======
</TABLE>
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING ACTIVITY:
During 1997, $425,000 of outstanding debentures along with $66,000 of accrued
interest were converted into 98,267 shares of Common Stock net of unamortized
debt issuance costs totaling $1,000.
5
<PAGE>
EMBREX, INC.
FORM 10-Q
June 30, 1997
NOTES TO CONSOLIDATED INTERIM CONDENSED FINANCIAL STATEMENTS (Unaudited)
NOTE 1 -- BASIS OF PRESENTATION
The accompanying unaudited financial statements include the accounts of Embrex,
Inc. and its wholly owned subsidiaries, Embrex Europe Limited and Embrex Sales,
Inc. (collectively referred to as the Company) and have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation
S-X. Accordingly, they do not include all of the information and notes required
by generally accepted accounting principles. In the opinion of management, all
adjustments (consisting of normal recurring accruals) considered necessary for a
fair presentation of financial condition and results of operations have been
included. Operating results for the six month period ended June 30, 1997 are not
necessarily indicative of the results that may be attained for the entire year.
For further information, refer to the financial statements and notes thereto
included in the Company's Form 10-K for the year ended December 31, 1996.
NOTE 2 - NET INCOME PER SHARE
Primary earnings per share are computed by dividing net income by the weighted
average number of shares of Common Stock and common stock equivalents
outstanding during the period. Common stock equivalents consist of stock
options, warrants, and common shares purchasable under the Employee Stock
Purchase Plan and are computed using the treasury stock method. The difference
between primary and fully diluted net income per common share is not significant
in all periods presented.
In February 1997, the Financial Accounting Standards Board issued Statement No.
128, EARNINGS PER SHARE, which is required to be adopted on December 31, 1997.
At that time, the Company will be required to change the method currently used
to compute earnings per share and to restate all prior periods. Under the new
requirements for calculating primary earnings per share, the dilutive effect of
stock options will be excluded. The impact of Statement 128 on the calculation
of fully diluted earnings per share is not expected to be material.
NOTE 3 - RECLASSIFICATION
Certain 1996 amounts in the accompanying financial statements have been
reclassified to conform to the presentation format adopted in the fourth quarter
of 1996. These reclassifications had no effect on previously reported net
income, loss, or stockholders equity.
6
<PAGE>
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations.
RESULTS OF OPERATIONS
Three Months Ended June 30, 1997 and 1996
Consolidated revenues for the second quarter of 1997 totaled $5.9 million,
representing a 17% increase of $854,000 over the same period in 1996. During
this time, the Company achieved a 22% increase of approximately $1 million in
INOVOJECT(R) system revenue to $5.6 million from $4.6 million during the
comparable period in 1996. Substantially all of the 1997 and 1996 INOVOJECT(R)
system revenues were derived from INOVOJECT(R) system lease fees, with the
growth in lease revenues primarily due to an 11% year-over-year increase in the
number of INOVOJECT(R) systems operating under lease agreements.
Reflecting the on-going delay associated with obtaining British regulatory
approval for the sale of Bursamune(TM) in the United Kingdom, revenue from
product sales declined 29% to $293,000 from the $413,000 recorded a year earlier
which included $262,000 attributable to sales to Fort Dodge Animal Health, a
division of American Home Products. The purchase by Fort Dodge reflected the
then-anticipated British regulatory approval. Overall, the Company realized
improved gross profit margin performance during the second quarter, achieving a
level of 51% compared to 47% in the 1996 period.
Operating expenses increased to $2.4 million for the second quarter of 1997, up
$555,000 from the comparable 1996 amount. The increase principally reflects
$348,000 attributable to general corporate expense associated with higher sales
and legal fees related to patent infringement matters; $103,000 relating to
enlarging the installed base of INOVOJECT(R) systems, as well as the cost of
expanding the Company's international presence in anticipation of the approval
of vaccines for IN OVO delivery; and $104,000 associated with product research,
development, and engineering.
Net interest expense decreased 49% from $315,000 in the 1996 period to $160,000
in 1997 due to the combination of diminishing interest expense payments on
INOVOJECT(R) system lease lines, and an increase in interest earned on
short-term investments.
The stronger bottom-line performance demonstrates the benefit of the Company's
focus on achieving INOVOJECT(R) system operating efficiencies and constraining
selling expenses, the combination of which enabled the Company to post record
second quarter net income. Net income of $417,000 for the quarter ended June 30,
1997 increased to 216% of the $193,000 profit earned during the comparable 1996
period. Earnings per share increased by 67%, to $.05 for the 1997 second quarter
versus $.03 per share in the comparable 1996 period. This improvement in
per-share earnings was achieved in spite of a 14% increase in the number of
weighted average shares of common stock outstanding, to 8.4 million shares
compared to 7.3 million at the end of the second quarter of 1996, chiefly
reflecting the issuance of shares pursuant to the exercise of outstanding
warrants and debentures.
7
<PAGE>
Six Months Ended June 30, 1997 and 1996
Consolidated revenues for the six months ended June 30, 1997 totaled $11.8
million, up 23% from $9.7 million a year earlier. This increase is principally
attributable to stronger INOVOJECT(R) system revenues which account for 95% of
the $11.8 million total. Consistent with the 11% increase from June 30, 1996 in
the number of INOVOJECT(R) systems installed under lease agreements,
INOVOJECT(R) system revenues showed a year-over-year increase of 26%, growing
$2.3 million to $11.3 million. Substantially all of the 1997 and 1996
INOVOJECT(R) system revenues were derived from INOVOJECT(R) system lease fees.
Cost of product and INOVOJECT(R) system revenues totaled $5.7 million (48% of
total revenues) for the first six months of 1997 compared to $5.2 million (53%
of total revenues) for the same 1996 period, resulting in first-half gross
margins of 52% and 47%, respectively.
Operating expenses for the six months ended June 30, 1997 increased to $4.9
million, up $1.5 million from the comparable 1996 amount. The increase
principally reflects $934,000 attributable to general corporate expense
associated with higher sales and legal fees related to patent infringement
matters; $234,000 relating to enlarging the installed base of INOVOJECT(R)
systems, as well as the cost of expanding the Company's international presence
in anticipation of the approval of vaccines for IN OVO delivery; and $337,000
associated with product research, development, and engineering.
Net interest expense decreased by $327,000 from $687,000 for the six months
ended June 30, 1996 to $360,000 for the same 1997 period. This 48% improvement
is the result of the combination of a $238,000 decrease in interest expense
attributable to reductions in lease and debt obligations, and an $89,000
increase in interest earned on short-term investment balances.
Net income for the six months ended June 30, 1997 of $679,000 represents 270% of
the $251,000 reported for the same period ended June 30, 1996. The increase of
$428,000 translates into earnings during the first half of 1997 that, at $.08
per weighted average share of common stock outstanding, equals 267% of the $.03
per weighted average share reported for the six months ended June 30,1996. This
improvement in first-half 1997 earnings was accompanied by a 16% increase of 1.1
million in the number of weighted average shares of common stock outstanding
from 7.2 million at June 30, 1996 to 8.3 million at June 30, 1997, chiefly
reflecting the issuance of shares pursuant to the exercise of outstanding
warrants and debentures.
Management anticipates further revenue growth throughout the balance of 1997
relative to the levels achieved in 1996. This growth is expected to come from
existing INOVOJECT(R) system operations in the United States and Canada, new
INOVOJECT(R) system leases in other countries, product sales of the Company's
proprietary viral neutralizing factor (VNF(R)) to vaccine manufacturers, and
sales of its Bursaplex(TM) (previously known as "BDA-BLEN") product to poultry
producers.
Bursaplex(TM), a product which combines the Company's VNF(R) compound with an
Infectious Bursal Disease vaccine, has received approval from the United States
Department of Agriculture for both post-hatch and IN OVO delivery in the United
States.
8
<PAGE>
Bursamune(TM), which also contains Embrex's VNF(R) compound, is produced by
Cyanamid Websters, the Australian affiliate of Fort Dodge Animal Health, a
division of American Home Products. Fort Dodge is the official registrant of
Bursamune(TM) in Europe, the Middle East, and Africa. Bursamune(TM) is under
regulatory review in certain countries in Europe and the Middle East. In June
1997, Fort Dodge indicated that its application for British regulatory approval
of Bursamune(TM) had been provisionally disapproved; however, the British
regulatory authority requested that further data be supplied. Both companies are
cooperating with the regulatory authority to supply the requested information
and it is anticipated that the review process will be completed in 1998.
Bursaplex(TM), a similar product, was approved for use in the United States in
1997.
The rate at which the marketplace will accept its INOVOJECT(R) system technology
outside the United States and Canada, the timing of approvals of third-party
vaccines for IN OVO use outside the United States, and production levels adopted
by domestic and foreign hatchery operators will impact the pace of revenue
growth and the ability of the Company to sustain, or improve, profitability from
the installation and operational throughputs of INOVOJECT(R) systems. Management
will continue to focus on operating efficiencies and revenue growth in an effort
to maintain or improve gross margins, and will continue to carefully balance
selling, operating, and interest expenses against its goal of continuing and
increasing profitability.
CHANGES IN FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES
At June 30, 1997, the Company's cash, cash equivalents and short-term investment
balances totaled $9.6 million, down approximately $300,000 from the $9.9 million
on hand at year-end 1996. Embrex believes it will be able to continue its use of
existing cash in conjunction with cash flow generated by operations to fund its
capital and continued international expansion during the balance of 1997.
Operating activities generated $2.8 million in cash during the first half of
1997, reflecting increases attributable to $679,000 in net income, $1.9 million
from depreciation and amortization, and $669,000 from increases in accounts
payable and accrued expenses, the total of which was then offset by $448,000
related to an increase in accounts receivable. During the same period, investing
activities consumed a net $801,000, principally due to the use of $1.7 million
for the purchase of INOVOJECT(R) systems to accommodate domestic and
international growth.
Net financing activities consumed $1.4 million during the period largely as a
result of repayments on capital lease obligations. In addition, proceeds from
the exercise of options to purchase common stock provided $185,000.
As of June 30, 1997 the Company had outstanding purchase commitments of
approximately $3.4 million related to the production of the Company's
Bursaplex(TM) product, and materials and supplies for the construction and
maintenance of INOVOJECT(R) egg injection systems. Additionally, in connection
with the January 1996 agreement reached with Select Laboratories (as discussed
in the Company's Form 10-K for the year ended December 31, 1996), the Company is
obligated to purchase all existing inventories of raw material, Bursaplex(TM),
and related materials from Select within thirty months following the January 20,
1997 receipt of IN OVO approval of the Bursaplex(TM) product being manufactured
for Embrex.
9
<PAGE>
Based on its current operations, management believes that its available cash and
short-term investments, together with cash flow from operations and existing
equipment financing lines, will be sufficient to meet its foreseeable cash
requirements.
FORWARD-LOOKING STATEMENTS
This report contains "forward-looking" statements. These statements involve
risks and uncertainties that could cause the Company's actual results to differ
materially from those in the forward looking statements, including without
limitation the Company's dependence on certain customers; the ability of the
Company, its manufacturing and marketing partners and others to obtain
regulatory approval for products to be delivered IN OVO, which are dependent on
a number of factors, including the results of trials, the discretion of
regulatory officials, and any potential changes in regulations; the Company's
ability to generate future cash flow from operations; continued demand for the
INOVOJECT(R) system; the Risk Factors described in the Company's Form 10-K for
the year ended December 31, 1996 (Exhibit 99); and other risks detailed from
time to time in the Company's Securities and Exchange Commission filings,
including the Company's reports on Forms 10-Q, 10-K, and 8-K.
Item 3. Quantitative and Qualitative Disclosures About Market Risk. Not
applicable.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
For a description of certain patent infringement proceedings initiated by the
registrant and related legal proceedings, see registrant's Form 10-K for the
year ended December 31, 1996 filed with the Securities and Exchange Commission
on March 31, 1997, as amended by Form 10-K/A filed with the Securities and
Exchange Commission on April 15, 1997.
Item 2. Changes in Securities.
On May 27, 1997, Embrex issued 34,320 shares of common stock in exchange for
substantially all of the assets of Agrimatic Corporation pursuant to a claim of
exemption from registration under Section 4(2) of the Securities Act of 1933, as
amended, based on representations made by Agrimatic in the Agreement and Plan of
Reorganization dated May 27, 1997 between the Company, Agrimatic, and certain
shareholders of Agrimatic.
Item 3. Defaults Upon Senior Securities. Not applicable.
10
<PAGE>
Item 4. Submission of Matters to a Vote of Security Holders.
On May 15, 1997 the Annual Shareholders meeting was held and the following
matters were submitted to the shareholders for a vote. There were 7,182,304
shares either present or evidenced by proxy and below represents a brief
description of the matters voted on and the number of votes cast for, against or
withheld, as well as the number of abstentions and broker non-votes.
ELECTION OF DIRECTORS:
<TABLE>
<CAPTION>
Votes Votes Votes
Director Votes For Withheld Against Abstained Totals
<S> <C> <C> <C> <C> <C>
Charles E. Austin 7,039,179 143,125 n/a n/a 7,182,304
Lester M. Crawford,
D.V.M., Ph.D. 7,079,319 102,985 n/a n/a 7,182,304
Stephen Hartogensis 7,044,089 138,215 n/a n/a 7,182,304
Randall L. Marcuson 7,029,319 152,985 n/a n/a 7,182,304
Kenneth N. May, Ph.D. 7,078,679 103,625 n/a n/a 7,182,304
Arthur M. Pappas 7,078,219 104,085 n/a n/a 7,182,304
</TABLE>
RATIFICATION OF INDEPENDENT AUDITORS:
Votes Votes Votes
Auditor Votes For Withheld Against Abstained Totals
Ernst & Young, LLP 7,115,881 n/a 52,120 14,303 7,182,304
Item 5. Other information. Not applicable.
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
27 - Financial Data Schedule.
(b) Reports on Form 8-K. Not applicable.
11
<PAGE>
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: August 12, 1997
EMBREX, INC.
By: /s/ Randall L. Marcuson
Randall L. Marcuson
President and Chief Executive Officer
By: /s/ Don T. Seaquist
Don T. Seaquist
Vice President, Finance and Administration
12
<PAGE>
Embrex, Inc.
File No. 000-19495
Form 10-Q
For the Quarterly Period
Ended June 30, 1997
EXHIBIT INDEX
Sequential
Exhibit Page Number
27 Financial Data Schedule
13
<PAGE>
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the
Registrant has caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: August 12, 1997
EMBREX, INC.
By:
Randall L. Marcuson
President and Chief Executive Officer
By:
Don T. Seaquist
Vice President, Finance and Administration
11
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> US-DOLLARS
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> JUN-30-1997
<EXCHANGE-RATE> 1
<CASH> 9,604
<SECURITIES> 0
<RECEIVABLES> 2,549
<ALLOWANCES> 0
<INVENTORY> 1,890
<CURRENT-ASSETS> 14,043
<PP&E> 23,647
<DEPRECIATION> (12,044)
<TOTAL-ASSETS> 25,646
<CURRENT-LIABILITIES> 6,495
<BONDS> 4,343
0
0
<COMMON> 82
<OTHER-SE> 14,726
<TOTAL-LIABILITY-AND-EQUITY> 25,646
<SALES> 11,847
<TOTAL-REVENUES> 11,847
<CGS> 5,733
<TOTAL-COSTS> 5,733
<OTHER-EXPENSES> 4,981
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 360
<INCOME-PRETAX> 773
<INCOME-TAX> 94
<INCOME-CONTINUING> 679
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 679
<EPS-PRIMARY> $0.08
<EPS-DILUTED> $0.08
</TABLE>
